FORM 4
[X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Steele John E.		 2. Issuer Name and Ticker or Trading Symbol

Convey Health Solutions Holdings, Inc. [ CNVY ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP, Technology
(Last)          (First)          (Middle)

C/O CONVEY HEALTH SOLUTIONS, 100 SE THIRD AVENUE, 26TH FLOOR		 3. Date of Earliest Transaction (MM/DD/YYYY)

10/7/2022
(Street)

FORT LAUDERDALE, FL 33394
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.01 per share (1)(2)(3)10/7/2022  D  182395 D$10.50 (3)5775 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) (4)(5)$7.94 10/7/2022  D     161214   (5)3/2/2030 Common Stock, par value $0.01 per share 161214  (4)0 D  
Stock Option (right to buy) (4)(5)$6.76 (6)10/7/2022  D     299394   (5)3/2/2030 Common Stock, par value $0.01 per share 299394  (4)0 D  
Stock Option (right to buy) (4)(7)$14 10/7/2022  D     111607   (7)6/15/2031 Common Stock, par value $0.01 per share 111607  (4)0 D  
Restricted Stock Units (8) (9)10/7/2022  D     30692   (9) (9)Common Stock, par value $0.01 per share 30692  (8)0 D  
Restricted Stock Units (8) (10)10/7/2022  D     162749   (10) (10)Common Stock, par value $0.01 per share 162749  (8)0 D  
Explanation of Responses:
(1) On October 7, 2022 (the "Closing Date"), Convey Health Solutions Holdings, Inc. (the "Company") completed the transaction pursuant to which Commodore Merger Sub 2022, Inc. ("Merger Sub") merged with and into the Company (the "Merger") with the Company surviving the Merger (the "Surviving Corporation"). Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of June 20, 2022, by and among Commodore Parent 2022, LLC, Merger Sub and the Company (the "Merger Agreement"), at the Effective Time (as defined in the Merger Agreement), each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and designated as Rollover Shares (as defined in the Merger Agreement) was automatically converted into 0.01 shares of common stock of the Surviving Corporation (the "Surviving Corporation Shares").
(2) In connection with the closing of the Merger, the Company notified the New York Stock Exchange (the "NYSE") on October 6, 2022 of the anticipated closing of the Merger on the Closing Date and that trading of the shares of Company common stock should be suspended and listing of the Company common stock on the NYSE should be removed prior to the opening of business on the Closing Date. On October 6, 2022, the closing price of a share of Company common stock was $10.51 per share.
(3) Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's shares of Company common stock issued and outstanding immediately prior to the Effective Time and not designated as Rollover Shares was converted into the right to receive $10.50 per share in cash, without interest.
(4) Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's options to acquire Company common stock, whether vested or unvested, remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that: (i) each such option is exercisable for that number of Surviving Corporation Shares equal to the product of (A) the number of shares of Company common stock subject to the option immediately before the Effective Time multiplied by (B) 0.01; and (ii) the per share exercise price for each Surviving Corporation Share issuable upon exercise of such option is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (A) the exercise price per share of such option immediately before the Effective Time by (B) 0.01.
(5) The options, together representing a right to purchase 460,608 shares, consist of (i) 230,304 time-vesting options and (ii) 230,304 performance-vesting options. Time-vesting options are subject to a five-year time-based vesting schedule, with 20% vesting on September 4, 2020 and the remainder vesting in 16 equal installments every three months thereafter. Performance-vesting options vest over a five-year performance period commencing in 2019, with 20% of the stock options eligible to vest each year of the performance period based on achievement of certain financial metrics.
(6) Exercise price reflects a reduction of $1.18 per award from original exercise price of $7.94 as part of a special dividend as previously disclosed in the Company's proxy statement for its 2022 annual meeting of stockholders.
(7) Represents 111,607 time-vesting options. Time-vesting options are subject to a four-year time-based vesting schedule, with 25% vesting on June 15, 2022, and the remainder vesting in 12 equal installments every three months thereafter, subject to Mr. Steele's continued service through the applicable vesting date.
(8) Subject to the terms and conditions of the Merger Agreement, at the Effective Time, each of the reporting person's outstanding Company restricted stock units ("RSUs") remained outstanding and continue to be subject to the same terms and conditions as immediately prior to the Effective Time, as set forth in the applicable plan and award agreement, except that each such RSU will settle in a number of Surviving Corporation Shares equal to the number of shares subject to the award immediately before the Effective Time multiplied by 0.01.
(9) Represents 30,692 RSUs, which is the unvested balance of 44,643 RSUs that were granted to the reporting person on June 15, 2021 subject to a four year time-based vesting schedule with 25% vesting on June 15, 2022, and the remainder vesting in 12 equal installments every three months thereafter, subject to Mr. Steele's continued service through the applicable vesting date. Prior to the Effective Time, each RSU represented a contingent right to receive one share of Company common stock and settled in common stock.
(10) Represents 162,749 RSUs. RSUs are subject to a four year time-based vesting schedule with 25% vesting on March 28, 2023, and the remainder vesting in 12 equal installments every three months thereafter, subject to Mr. Steele's continued service through the applicable vesting date. Prior to the Effective Time, each RSU represented a contingent right to receive one share of Company common stock and settled in common stock.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Steele John E.
C/O CONVEY HEALTH SOLUTIONS
100 SE THIRD AVENUE, 26TH FLOOR
FORT LAUDERDALE, FL 33394

EVP, Technology
Signatures
/s/ Giovanni Castellanos, attorney-in-fact for John E. Steele10/12/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Convey Health Solutions (NYSE:CNVY)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Convey Health Solutions Charts.
Convey Health Solutions (NYSE:CNVY)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Convey Health Solutions Charts.